Repeated cellular stress due to aging and lifestyle-related activities causes tissue damage. That damage is repaired by a homeostatic process consisting first of acute inflammation and then of adaptive physiologic tissue remodeling meditated by communication between parenchymal and stromal cells. That signaling can occur via cell-to-cell contact or through secreted factors. However, excessive or prolonged stress leads to chronic inflammation and pathologic tissue remodeling, perturbing homeostasis and promoting development of lifestyle-related diseases or cancer. Expression of Angiopoietin-like protein 2 (ANGPTL2) is induced both normally and by diseaseassociated stresses. In the former, ANGPTL2 promotes proper adaptive inflammation and tissue reconstruction and thus maintains homeostasis; however, in the latter, excess ANGPTL2 activation impairs homeostasis due to chronic inflammation and irreversible tissue remodeling, promoting metabolic and atherosclerotic diseases and some cancers. Thus, it is important to define how ANGPTL2 signaling is regulated in order to understand mechanisms underlying tissue homeostasis and disease development. Here, we focus on ANGPTL2 function in these activities and discuss whether excess ANGPTL2 function is a common molecular mechanism underlying lifestyle diseases and cancer.
Introduction
Various external and internal stresses due to aging and lifestyle cause tissue damage in organs. Such damage is normally repaired first by acute inflammation and then by physiologic tissue remodeling 1) . These activities are regulated primarily by communication between parenchymal and stromal cells via either direct cell-to-cell contact and/or by paracrine mechanisms mediated by secreted factors 1) .
However, excess stress leads to continuous unresolved inflammation and subsequent irreversible tissue remodeling associated with metabolic diseases, such as obesity, glucose or lipid metabolism diseases, atherosclerosis, and even some forms of cancer 2) . Thus prevention of these diseases requires clarification of molecular mechanisms underlying breakdown of normal tissue homeostasis.
The angiopoietin-like protein (ANGPTL) family
The proteins angiopoietin-1, -2, -3 and -4 (ANGPT-1, and ANGPTL4 regulate lipid metabolism by inhibiting lipoprotein lipase activity 6) . The activity of ANGPTL6, also known as "angiopoietin-like growth factor" (AGF), reportedly counteracts obesity by increasing systemic energy expenditure and thus antagonizing related metabolic diseases [7] [8] [9] . More recently, ANGPTL8/betatrophin has been shown to function in triglyceride (TG) 10) and glucose metabolism 11) .
In several studies, we have reported that normal ANGPTL2 signaling functions in angiogenesis and tissue repair 5, [12] [13] [14] , while excess ANGPTL2 signaling causes chronic inflammation and irreversible tissue remodeling, leading to development of obesity, metabolic disease, type 2 diabetes, atherosclerotic disease, and some cancers 12, [14] [15] [16] [17] [18] .
Thus, excessive ANGPTL2 signaling is a potential common molecular mechanism underlying all of these conditions.
ANGPTL2 function in tissue remodeling
The presence of a C-terminal fibrinogen-like domain suggests that ANGPTL2 binds integrin receptors 19) . We have shown that ANGPTL2 binds to and signals through integrin α5β1 12) . In brief, we reported that via integrin α5β1 ANGPTL2 enhances cell motility by activating the Rho family GTPase Rac1 and increasing degradation of IκB, a factor that inhibits nuclear localization of nuclear factor κB (NF-κB). Thus ANGPTL2 signaling induces expression of inflammation-related NF-κB target genes 12) . Moreover, ANGPTL2 activates extracellular matrix (ECM) remodeling by upregulating and activating p38 mitogen-activated protein kinase (MAPK)-dependent matrix metalloproteinases (MMPs) 18) . Thus, ANGPTL2 signaling through integrin α5β1 increases cell motility, tissue inflammation, and ECM remodeling, resulting in subsequent tissue remodeling ( Fig.   2) 14)
. . ANGPTL2 is abundantly expressed in visceral adipose tissues and those levels increase in dietinduced obese mice 12) . As obesity develops, increased adipose tissue-secreted ANGPTL2 contributes to adipose tissue remodeling by promoting angiogenesis, macrophage recruitment, and ECM remodeling in order to store excess lipids into adipocytes (Fig. 3A) 14)
. . These studies suggest that increased adipose tissue-secreted ANGPTL2 in response to excessive food intake is a physiological response to store excess lipid into adipocytes and contributes to adipose tissue remodeling. However, in severe obesity, excess ANGPTL2 signaling leads to irreversible adipose tissue remodeling with chronic inflammation, resulting in metabolic diseases, such as obesity-related insulin resistance or type 2 diabetes (Fig. 3A) 14)
.
In obese mice, circulating levels of ANGPTL2 increase in parallel with ANGPTL2 expression in visceral adipose tissues and adipose tissue inflammatory status 12) . In a human study, circulating ANGPTL2 concentrations have been positively correlated with systemic insulin resistance in diabetes patients 12) . A 7-year follow-up of an epidemiological study of a general population with no history of diabetes showed that elevated serum ANGPTL2 levels are positively associated with future de novo development of type 2 diabetes, independent of other risk factors, including highsensitivity C-reactive protein (hs-CRP) levels 21) . Moreover, in overweight subjects, decreased serum ANGPTL2 levels reflect positive effects of lifestyle intervention in terms of weight loss and improved metabolic parameters, such as TG and/or insulin activity and the homeostasis model assessment-insulin resistance (HOMA-IR) index 22) . These findings suggest that high circulating ANGPTL2 levels 
ANGPTL2-induced chronic inflammation links obesity and associated metabolic disease to atherosclerotic disease
Coronary heart disease (CHD) is the major common form of cardiovascular disease (CVD), and its underlying pathology is atherosclerosis 23) . Recently, investigators have recognized that atherosclerosis progression, including plaque instability, is associated with chronic inflammation in the vessel wall and is a risk factor for major CHD events 24) .
Therefore, therapies designed to inhibit chronic inflammation in vessel walls could slow atherosclerosis progression. In addition, chronic adipose tissue inflammation, previously recognized as a leading cause of metabolic disturbance in obesity, is now known to be a predisposing factor for CHD;
however, mechanisms linking these conditions have not been identified. Perivascular adipose tissue-secreted proinflammatory adipokines, such as TNF-α, contribute to CVD development and enhance vascular remodeling 25, 26) . By contrast, anti-inflammatory adipokines, such as adiponectin, suppress neointimal hyperplasia after endovascular injury.
ANGPTL2 also is expressed in mouse perivascular adipose tissues surrounding the femoral artery at levels equivalent to those seen in visceral adipose tissues 27) . In this context, ANGPTL2 accelerates vascular inflammation, pathologic vascular tissue remodeling and subsequent CVD development 28) . Abundant ANGPTL2 expression in endothelial cells also occurs with obesity and associated metabolic disturbances, and is viewed as a predisposing condition for atherosclerotic disease 15) . Increases in endothelial cell-derived ANGPTL2 expression in these conditions thus promotes vascular inflammation and associated pathologies (Fig. 3B) . Moreover, several lines of evidence demonstrate that endothelial cell dysfunction in fact worsens diabetes and obesity by exacerbating insulin resistance and metabolic disturbance 29, 30) . Overall, these findings suggest that ANGPTL2 links metabolic disorders seen in obesity to . In the early phases of obesity (mild obesity), increased ANGPTL2
secretion from adipose tissues promotes MMP activation and induces adipose tissue remodeling. These activities promote angiogenesis and ECM remodeling, leading to adipogenesis and adipocyte hypertrophy. Lifestyle changes, such as overnutrition or inactivity, induce higher adiposity (severe obesity) and result in excess ANGPTL2 secretion and enhanced vascular inflammation and macrophage infiltration into adipose tissue. These conditions lead to chronic inflammation and subsequent pathologic adipose tissue remodeling, resulting in obesity-related insulin resistance and type 2 diabetes.
(B)ANGPTL2 links metabolic disorders seen in obesity to CVD. Perivascular adipose tissue-secreted ANGPTL2 accelerates vascular inflammation, pathologic vascular tissue remodeling and subsequent CVD development. ANGPTL2 expression in endothelial cells is also abundantly induced by obesity and associated metabolic dysregulation and is a predisposing condition for atherosclerotic disease. Increased endothelial cell-derived ANGPTL2 due to obesity and/or metabolic disturbance promotes vascular inflammation, leading to endothelial dysfunction and atherosclerosis. as infiltrating cells 32, 33) . In these conditions, increased ANGPTL2 secretion in vascular tissue accelerates vascular tissue inflammation and pathological remodeling, leading to atherosclerotic disease progression 15, 28, 34, 35) . Further clinical investigation is needed to determine whether reduction of circulating or tissue ANGPTL2 levels would constitute an effective treatment for CVD patients.
ANGPTL2 function in carcinogenesis
Cancer is a major cause of mortality and is increasing world-wide; thus identification of molecular and cellular mechanisms underlying its pathogenesis is critical. Chronic inflammation and pathological tissue remodeling occur at all stages of cancer development, including carcinogenesis, invasion, and metastasis 36) . For example, in skin tissue, sun exposure or aging normally upregulates ANGPTL2 to repair tissue damage by first inducing inflammation and then promoting tissue remodeling 14, 16) . However, repetitive, severe skin damage promotes excessive and prolonged ANGPTL2 induction. Interestingly, unregulated ANGPTL2
signaling epigenetically silences expression of mutator small subunit homologue 2 (Msh2 ), which encodes a DNA mismatch repair enzyme, thereby increasing genomic microsatellite instability and rates of DNA replication errors 37) .
Thus, inappropriate ANGPTL2 signaling causes pathological tissue inflammation and increases carcinogenesis susceptibility through inactivation of DNA repair, an aberration . Normally, ANGPTL2 secretion promotes tissue remodeling and maintains tissue homeostasis. However, prolonged stresses due to aging or exposure to UV light or chemical compounds increase ANGPTL2 expression and secretion, resulting in chronic inflammation. Chronic inflammation increases cancer susceptibility by inducing oxidative stress, which promotes DNA damage and genomic instability.
(B)Molecular mechanisms underlying ANGPTL2-mediated tumor metastasis 14) . The hypoxic, nutrient-poor tumor microenvironment induces 
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that likely enables accumulation of oncogenic mutations (Fig. 4A ) 14, 16) .
ANGPTL2 function in metastasis
Tumor metastasis decreases survival of many cancer patients. The tumor microenvironment, which consists of stromal cells, including immune cells, fibroblasts, and endothelial cells, is a major factor in metastatic activity as it affects tumor cell proliferation, survival, migration, and invasion 37) . A hypoxic microenvironment poor in nutrients such as glucose or amino acids is unfavorable to primary tumor cell growth and survival and thus encourages acquisition of aggressive phenotypes to enhance invasion and metastasis 38, 39) . Interestingly, hypoxia and undernutrition are associated with induction of genes encoding demethylase-related enzymes, resulting in demethylation and subsequent activation of the ANGPTL2 promoter 18) .
Furthermore, ANGPTL2 expression is increased by activating nuclear factor of activated T-cells, cytoplasmic (NFATc), activating transcription factor 2 (ATF2), and c-Jun 17) − all transcription factors activated by hypoxia, oxidative stress, and endoplasmic reticulum (ER) stress conditions 40) commonly observed in the tumor microenvironment 41) .
Thus, ANGPTL2 expression in tumor cells is increased by both epigenetic modification 18, 42) and microenvironmentdependent transcriptional activation 17) (Fig. 4B) 14)
. Increased ANGPTL2 expression in turn promotes tumor cell invasion and angiogenesis in an autocrine/paracrine manner ( Fig.   4B ) 14) . In mouse xenograft models, tumor cell-derived ANGPTL2 accelerates metastasis and shortens survival periods, while decreasing ANGPTL2 expression in those cells significantly attenuates metastasis and extends survival 17, 18) , suggesting that ANGPTL2 suppression could be a potential strategy to decrease tumor metastasis. More recently, it was reported that serum ANGPTL2 levels are associated with pathological progression of some tumor types 43) . Further studies are needed to investigate whether serum ANGPTL2 levels could serve as a biomarker to assess tumor progression and/or metastasis in particular tumor subtypes.
Effects of inhibiting ANGPTL2 biological activity on tumor progression
Culture supernatants of the human embryonic kidney line HEK293 transfected with an ANGPTL2 expression vector contain not only full-length ANGPTL2 protein but also ANGPTL2 cleavage fragments, suggesting that the protein undergoes proteolytic processing 18) . In fact,
cleavage of ANGPTL2 by tolloid-like 1 (TLL1), a member of bone morphogenetic protein-1 (BMP-1)/tolloid (TLD) family of proteinases 44, 45) , abrogates the ability of the fulllength protein to promote tumor progression 18) . On the other hand, cleavage fragments of endogenous ANGPTL2
have not been observed in culture supernatants of tumor cells, whose metastatic activity is accelerated by tumor cellsecreted ANGPTL2 18) . Interestingly, TLL1 expression levels in tumor cells are extremely low compared with that seen in HEK293 cells, and no mutations in a potential ANGPTL2
cleavage site have been identified in tumor cells, suggesting that extremely low TLL1 expression may underlie poor ANGPTL2 cleavage in these cells 18) . Moreover, TLL1
is reportedly silenced by aberrant methylation of its 5'-upstream region in human pancreatic cancers 46) , and recent findings reveal that some human pancreatic cancer lines abundantly secrete full-length ANGPTL2 18) . These studies suggest that TLL1 levels in some human tumors are not sufficient to cleave endogenous ANGPTL2. Thus one novel strategy that could be exploited therapeutically to inactivate ANGPTL2 would be to promote its cleavage.
These findings also suggest that compounds capable of increasing TLL1 expression or activity in a primary tumor could serve as anti-metastatic drugs.
Other groups have reported that a single nucleotide polymorphism (SNP) located in TLL1 intron 12 (a single human TLL1 variant rs1503298) is positively associated with coronary artery disease (CAD) in patients with type 2 diabetes and CAD 47) , however, the molecular mechanisms of relationship between the SNP and CAD development remains unknown. Serum ANGPTL2 significantly increases in patients with type 2 diabetes or CAD 8, 12) , and ANGPTL2-associated inflammation and pathologic tissue remodeling contribute to development of these diseases 9) . Taken together, these findings suggest that promoting TLL1-mediated ANGPTL2 cleavage could serve as a novel therapeutic strategy for type 2 diabetes and CAD as well as a way to block tumor progression and metastasis.
Circadian regulation of ANGPTL2 expression
Several important physiological and behavioral processes exhibit circadian rhythmicity 48, 49) . Periodic expression or secretion of hormones and cytokines is critical to maintain in vivo homeostasis 50) . Mice showing disrupted circadian rhythms exhibit metabolic pathologies, such as hypertension, lipid or glucose metabolic disease, or some cancers 51) . The mammalian circadian system is composed of core clock genes that encode proteins such as circadian locomotor output kaput (CLOCK), brain and muscle aryl hydrocarbon receptor nuclear translocator (ARNT)-like protein 1 (BMAL1), period (PER), and cryptochrome (CRY) 50, 52, 53) . Both Angptl2 mRNA and protein, which are widely expressed in many mouse tissues 12) , show circadian rhythmicity and have been shown to be regulated by core clock genes in some tissues 54, 55) . Dysregulation of periodic .
Concluding remarks
In this review, we have focused on diverse ANGPTL2 functions in both normal and pathological conditions.
In the former, ANGPTL2 signaling is critical for tissue homeostasis; in the latter, however, excess and prolonged ANGPTL2 signaling leads to chronic inflammation and pathologic tissue remodeling, triggering a breakdown in tissue homeostasis. Circadian regulation of ANGPTL2 might contribute to maintenance of tissue homeostasis, and dysregulation of ANGPTL2 expression likely contributes to development and progression of metabolic diseases and even some cancers (Fig. 5B) 14)
. Moreover, circulating ANGPTL2 levels may serve as a biomarker of whether tissue homeostasis is proceeding in a physiological or pathological manner. Suppression of excess and prolonged ANGPTL2 signaling might represent a novel and effective therapeutic strategy against metabolic diseases and cancer.
In advance of clinical applications, further pre-clinical studies are necessary using patient tissues. . External and internal stresses due to aging or lifestyle damage tissues, which are normally repaired via tissue remodeling by interactions of parenchymal with stromal cells, either directly or via humoral factors. ANGPTL2
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contributes to tissue repair by inducing such remodeling, while its periodic expression or secretion maintains homeostasis.
(B)Loss of ANGPTL2 periodicity and development of lifestyle diseases and cancer 14) . Periodic ANGPTL2 expression maintains tissue homeostasis; however, prolonged stresses induce loss of periodicity of ANGPTL2 transcription. Continuous ANGPTL2 expression causes chronic inflammation and subsequent pathologic irreversible tissue remodeling, resulting in development and progression of lifestyle diseases and cancer. 
